Explore the words cloud of the DDRNA project. It provides you a very rough idea of what is the project "DDRNA" about.
The following table provides information about the project.
Coordinator |
IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE
Organization address contact info |
Coordinator Country | Italy [IT] |
Total cost | 149˙425 € |
EC max contribution | 149˙425 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2014-PoC |
Funding Scheme | ERC-POC |
Starting year | 2015 |
Duration (year-month-day) | from 2015-06-01 to 2016-11-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE | IT (MILANO) | coordinator | 149˙425.00 |
The so-called “DNA damage response” (DDR) is a coordinated set of evolutionary-conserved events that, triggered upon DNA damage detection, arrests the cell-cycle and attempts DNA repair. Recently, we have unveiled and reported that DDR activation depends on RNA. We observed that DNA double-strand breaks (DSBs) trigger the local generation of small non-coding RNAs at the site of DNA damage carrying the sequence surrounding the damaged site. These DDR RNAs (DDRNAs) are essential for DDR activation: removal of DDRNAs by RNAse A treatment of permeabilized cells inhibits DDR activation and DDR can be fully restored by the addition of chemically-synthesized DDRNA carrying the sequence surrounding the damaged site but not other sequences (Francia, Nature 2012). Cancer cells must preserve unlimited proliferative potential. We have previously shown that oncogene activation (and therefore cell transformation) is associated with DDR activation at fragile sites (Di Micco, Nature 2006). Several studies have shown that RNA functions can be inhibited by antisense oligonucleotides (ASO) that act by pairing with target RNAs. We propose scientific development and commercialization activities to bring to a clinical application a therapeutic approach for tumors based on DDRNA inhibition by ASO. Analysis of prior art indicate that there is no overlapping IP protection. Based on our solid IPR, we trust we have an excellent candidate for a first-in-class tool to block proliferation in a subtype of tumors.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DDRNA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "DDRNA" are provided by the European Opendata Portal: CORDIS opendata.